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a  b  s  t  r  a  c  t
Despite  long-recognized  challenges  and  constraints  associated  with  their  updating  and manufacture,
inﬂuenza  vaccines  remain  at the heart  of  public  health  preparedness  and  response  efforts  against  both
seasonal  and  potentially  pandemic  inﬂuenza  viruses.
Globally  coordinated  virological  and  epidemiological  surveillance  is  the  foundation  of the  inﬂuenza
vaccine  virus  selection  and  development  process.  Although  national  inﬂuenza  surveillance  and  reporting
capabilities  are  being  strengthened  and  expanded,  sustaining  and  building  upon  recent gains  has  become
a  major  challenge.
Strengthening  the  vaccine  virus  selection  process  additionally  requires  the  continuation  of  initiatives
to  improve  the  timeliness  and  representativeness  of  inﬂuenza  viruses  shared  by countries  for  detailed
analysis  by  the WHO  Global  Inﬂuenza  Surveillance  and  Response  System  (GISRS).
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Efforts  are  also  continuing  at the  national,  regional,  and  global  levels  to  better  understand  the dynamics
of inﬂuenza  transmission  in both  temperate  and tropical  regions.  Improved  understanding  of the  degree
of  inﬂuenza  seasonality  in  tropical  countries  of  the world  should  allow  for the  strengthening  of national
vaccination  policies  and  use  of  the  most  appropriate  available  vaccines.
There  remain  a  number  of  limitations  and  difﬁculties  associated  with  the  use of HAI  assays  for  the
antigenic  characterization  and  selection  of  inﬂuenza  vaccine  viruses  by WHOCCs.  Current  approaches  to
improving  the  situation  include  the  more-optimal  use of HAI  and  other  assays;  improved  understanding  of
the  data  produced  by  neutralization  assays;  and  increased  standardization  of  serological  testing  methods.
A  number  of  new  technologies  and  associated  tools  have the  potential  to revolutionize  inﬂuenza  surveil-
lance and response  activities.  These  include  the  increasingly  routine  use  of whole  genome  next-generation
sequencing  and  other  high-throughput  approaches.  Such  approaches  could  not only  become  key  ele-
ments  in  outbreak  investigations  but could  drive  a new  surveillance  paradigm.  However,  despite  the
advances  made,  signiﬁcant  challenges  will  need  to be addressed  before  next-generation  technologies
become  routine,  particularly  in  low-resource  settings.
Emerging  approaches  and techniques  such  as synthetic  genomics,  systems  genetics, systems  biology
and mathematical  modelling  are  capable  of  generating  potentially  huge  volumes  of highly  complex  and
diverse  datasets.  Harnessing  the  currently  theoretical  beneﬁts  of such  bioinformatics  (“big data”)  concepts
for  the inﬂuenza  vaccine  virus  selection  and  development  process  will  depend  upon  further  advances  in
data  generation,  integration,  analysis  and  dissemination.
Over the  last  decade,  growing  awareness  of inﬂuenza  as an  important  global  public  health  issue has  been
coupled  to  ever-increasing  demands  from  the  global  community  for more-equitable  access  to  effective
and  affordable  inﬂuenza  vaccines.  The  current  inﬂuenza  vaccine  landscape  continues  to be dominated  by
egg-based  inactivated  and live  attenuated  vaccines,  with  a  small  number  of  cell-based  and  recombinant
vaccines.  Successfully  completing  each  step  in the  annual  inﬂuenza  vaccine  manufacturing  cycle  will
continue  to rely  upon  timely  and  regular  communication  between  the  WHO  GISRS, manufacturers  and
regulatory  authorities.
While the pipeline  of  inﬂuenza  vaccines  appears  to be  moving  towards  a variety  of  niche  products  in  the
near term,  it is  apparent  that  the  ultimate  aim remains  the  development  of  effective  “universal”  inﬂuenza
vaccines  that  offer longer-lasting  immunity  against  a broad  range  of  inﬂuenza  A  subtypes.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
For over 60 years the WHO  Global Inﬂuenza Surveillance and
Response System (GISRS)1 has served as the foremost global coordi-
nation mechanism for monitoring and responding to the evolution
and spread of inﬂuenza viruses, and ensuring the use of the most
up-to-date vaccine formulations. The GISRS vaccine virus selec-
tion process involves the coordinated collection and laboratory
analysis of hundreds of thousands of clinical specimens each year,
with the goal of determining which vaccine compositions will
best protect against disease during upcoming northern and south-
ern hemisphere inﬂuenza seasons. Due to severe time and other
production constraints inherent in current inﬂuenza vaccine man-
ufacturing technologies, the vaccine virus selection process must
be completed almost a year in advance of the predicted peak
of inﬂuenza activity in the season in which the vaccine is to be
used. The GISRS also continually monitors and assesses the risks
posed by potential pandemic viruses and provides guidance on
appropriate public health responses. In recent years, data simi-
lar to that used for seasonal inﬂuenza vaccine development have
been used to select viruses for use in 2009 A(H1N1) pandemic
vaccines, and in vaccines against other inﬂuenza virus subtypes,
including A(H5), A(H7) and A(H9) for pandemic preparedness
purposes.
In 2010, the convening of the ﬁrst WHO  Informal Consulta-
tion for Improving Inﬂuenza Vaccine Virus Selection provided
a unique opportunity to review in detail this highly complex
and collaborative process [1]. Building upon the outcome of
this review, a second consultation was held in 2011 to discuss
1 Formerly known as the Global Inﬂuenza Surveillance Network prior to the adop-
tion of the World Health Assembly Resolution WHA  64.5 on 24 May  2011. As of May
2014, the GISRS consisted of 141 National Inﬂuenza Centres (NICs) in 111 countries,
six  WHO  Collaborating Centres (WHOCCs), 12 WHO  H5 Reference Laboratories and
four WHO  Essential Regulatory Laboratories (ERLs).
the key principles of inﬂuenza surveillance and representative
virus sharing, the virological characterization of candidate vac-
cine viruses, vaccine manufacturing and regulatory requirements,
and the potential application of new and emerging vaccine
technologies [2]. In the intervening period between these two
meetings, the Pandemic Inﬂuenza Preparedness (PIP) Frame-
work for the sharing of inﬂuenza viruses and access to vaccines
and other beneﬁts was adopted. This important milestone event
reﬂected growing recognition of the importance of the timely
sharing and characterization of viruses, and of the equitable
provision of effective vaccines against both seasonal and pan-
demic inﬂuenza. In response, WHO  has continued working to
improve knowledge of the global patterns of inﬂuenza activity;
support the development of informed national policies, aided by
the work of its Strategic Advisory Group of Experts (SAGE) on
Immunization; increase global inﬂuenza production capacity and
supply as part of its Global Action Plan for Inﬂuenza Vaccines
(GAP); and promote expanded access to vaccines under the PIP
Framework.
Since the re-emergence of human cases of H5N1 inﬂuenza (“bird
ﬂu”) in 2003 and the 2009 H1N1 pandemic, growing awareness
of inﬂuenza as an important threat to public health has driven
an expansion of surveillance and response capacities in many
countries. Nevertheless, many countries are now facing major chal-
lenges in sustaining and building upon the gains made. In light of
recent national, regional and global initiatives to promote efﬁcient
surveillance and representative virus sharing, allied to ongoing
advances in vaccine development and production technologies, it
was felt timely to convene a third WHO  informal consultation in
order to:
• update participants on the progress made since the previous
meeting;
• further discuss surveillance as the foundation of vaccine virus
selection;
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• discuss newly emerging insights into the circulation and viro-
logical characteristics of inﬂuenza in tropical regions with the
potential to strengthen vaccine composition and deployment
decisions;
• discuss new assays, new technologies and new approaches and
their potential for bringing about improvements in both vaccine
effectiveness and manufacturing efﬁciency;
• discuss the regulatory and other practical issues that must be
considered in relation to both existing and emerging vaccine
technologies; and
• continue to provide a forum for stakeholders to review and
evaluate potential improvements to the inﬂuenza vaccine virus
selection process.
Approximately 128 participants drawn from 51 countries cov-
ering all six WHO  regions, and representing a wide range of WHO
partner organizations and other stakeholders attended (Annex
2). Participants were drawn from WHO  Collaborating Centres
(WHOCCs), WHO  Essential Regulatory Laboratories (ERLs), National
Inﬂuenza Centres (NICs), WHO  H5 Reference Laboratories, the
academic research community, National Regulatory Authorities
(NRAs), national public health agencies, veterinary institutions and
organizations, vaccine manufacturers, donor agencies and other
stakeholders.
2. Strengthening inﬂuenza surveillance and improving the
representativeness, timeliness and availability of candidate
inﬂuenza vaccine viruses
2.1. Efforts at national, regional and global levels
National inﬂuenza surveillance, reporting and response capabil-
ities continue to be strengthened and expanded in many countries,
particularly during and since the 2009 H1N1 pandemic. How-
ever, despite increasing awareness of the incidence, transmission
and disease burden associated with both seasonal and year-round
inﬂuenza activity, and the continuing pandemic threats posed
by A(H5N1) and other zoonotic viruses, sustaining and building
upon recent gains has become a major challenge. Key elements in
strengthening and sustaining inﬂuenza surveillance and response
systems include:
• National surveillance system building;
• National laboratory capacity building;
• improved reporting and virus-sharing procedures;
• enhanced capacity to rapidly detect and respond to zoonotic
inﬂuenza outbreaks.
Recent national surveillance system building efforts in Viet
Nam have included the establishment of hospital-based sentinel
screening for severe acute respiratory infection (SARI). The prompt
transfer of clinical samples to laboratories allows for feedback to
the participating sentinel sites and simultaneous onward repor-
ting of results to national authorities. However, these activities
currently rely upon external funding from the United States Cen-
ters for Disease Control and Prevention (CDC) and the number
of sentinel sites is decreasing. The viruses and data shared may
therefore not be fully representative in terms of geography, cli-
mate, age groups and epidemic timing. Selecting representative
viruses to send to a WHOCC is further complicated by the two
peaks of inﬂuenza activity typically observed in tropical countries.
As in many other settings, obtaining good-quality denominator
data in hospitals to produce meaningful estimates of the real bur-
den of disease caused by inﬂuenza is also problematic. Efforts to
improve reporting and virus-sharing procedures have included the
production of a widely circulated weekly newsletter summarizing
national inﬂuenza activity, weekly reporting to the WHO  FluNet
platform and the submission of representative circulating viruses to
a WHOCC. As a result, the quality of data on the impact and seasona-
lity of inﬂuenza in Viet Nam has improved, along with the ability to
rapidly detect inﬂuenza outbreaks and monitor circulating viruses
in the context of national prevention and control efforts.
In terms of national laboratory capacity building, the challenges
experienced in Pakistan illustrate the issues NICs facing in many
countries as inﬂuenza activities compete for funding with other
public health priorities. Foremost among these is ensuring the sus-
tainability of funding to meet the running costs of laboratories,
and maintain the momentum of recent capacity-building activi-
ties. In addition, virus-isolation rates are low and more training in
the required skills is needed for laboratory staff. Retaining suitably
qualiﬁed, trained and motivated staff at all levels of any national
system will be a key factor in ensuring the quality, completeness,
relevance and timeliness of virus sharing and data reporting.
In Madagascar, the national inﬂuenza sentinel surveillance net-
work monitors and reports upon both SARI and inﬂuenza-like
illness (ILI) across ﬁve different bio-climates. The network is based
upon both clinical and biological surveillance activities, with spec-
imens submitted weekly to the NIC for analysis. Data-collection
and reporting activities include the production of a weekly report
on national inﬂuenza activity; daily and event-speciﬁc sharing of
epidemiological data with the Ministry of Health; regular feed-
back of laboratory results to sentinel sites; and weekly reporting
to the WHO  FluNet platform and to the WHO  Regional Ofﬁce for
Africa. In common with all NICs, the Madagascar NIC aims to ensure
the representativeness of the virus types and subtypes submit-
ted to WHOCCs, with all unsubtypable viruses promptly shipped
to a WHOCC for further investigation. Future strengthening activ-
ities include the provision of support to regional (sub-national)
collaborating laboratories, conducting cost-effectiveness analyses
to enhance the sustainability of national inﬂuenza surveillance
activities and research into topics with particular relevance to
Madagascar. These include understanding the aetiology of viral
ILI (and factors associated with its severity) through integrated
genomic, immunological and other approaches; the spatiotempo-
ral dynamics of inﬂuenza virus circulation; and estimating the risk
of human infections caused by swine inﬂuenza viruses by identify-
ing the genetic and antigenic characteristics of viruses that infect
both humans and animals.
Experiences gained in China during the strengthening of
national inﬂuenza surveillance capacities and capabilities – includ-
ing for the detection of zoonotic inﬂuenza outbreaks – have
provided valuable insights that may  be highly applicable to other
countries and regions. Following its rapid expansion since 2009
(Fig. 1), the Chinese National Inﬂuenza Surveillance Network (NISN)
comprised 408 network laboratories and 554 sentinel hospital sites
by 2013. In that same year, the NISN was  able to rapidly detect
and characterize A(H7N9) and A(H10N8) viruses causing human
infections. In the case of H10N8, this rare infection was detected
through the Pneumonia of Unknown Etiology system, highlighting
the importance of having the necessary testing and reporting sys-
tems in place. For H7N9, conﬁrmed human cases were reported to
WHO  on 31 March 2013 with candidate vaccine viruses published
on the WHO  website by 10 May  followed on 31 May  by formal WHO
vaccine virus recommendations.
The WHOCC Beijing promotes a national strategy which
places laboratory capacity-building at the centre of surveillance-
strengthening efforts. Important principles identiﬁed in achieving
the goals of national surveillance include the collection, reporting
and consolidation of data, along with regular data analysis and
interpretation. Continuous efforts are required to detect, evaluate
and respond to any unusual patterns in the data. The quality of
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Fig. 1. Expanded and improved inﬂuenza surveillance laboratory capacity in China.
laboratory testing and related activities is assessed through partic-
ipation in both national and international initiatives. These include
a well-established national quality-evaluation system based upon
core timeliness and performance indicators, and the WHO  External
Quality Assessment Project (EQAP) for the detection of inﬂuenza
viruses by polymerase chain reaction (PCR).
Recent initiatives at the regional level have included a study
of the patterns of inﬂuenza virus submission by countries in the
WHO  European Region. Despite being the cornerstone of GISRS
vaccine virus selection activities, and a crucial element in meet-
ing the obligations of the PIP Framework, no systematic analysis
had previously been made of the temporal and epidemiological
representativeness of the viruses shared with WHOCCs, or of the
timeliness of such sharing in relation to the February WHO  Vac-
cine Composition Meeting (VCM). An analysis was  made of the
inﬂuenza surveillance samples submitted by NICs in the region to
the WHOCC London over two seasons (2010–11 and 2011–12). The
degree of completeness of data provided in conjunction with each
virus sample was also evaluated. Aggregated data for both seasons
indicated that a total of 2954 viruses were shared, with 1741 (59%)
collected prior to the February VCM deadline; however, only 946
viruses (32%) were shipped in time for consideration by the VCM.
This overall ﬁgure also masked clear sub-regional variations, with a
number of highly signiﬁcant sub-regions being underrepresented.
The average periods between specimen collection and shipment
were 90 days and 54 days for the ﬁrst and second seasons respec-
tively, with both the numbers of viruses submitted and delays in
their shipping varying signiﬁcantly between different sub-regions.
Missing data precluded further analysis of the level of demographic
and epidemiological representatives achieved over the two  sea-
sons. Future study objectives include determining the causes of
limited, late or lack of isolate sharing in some countries and sub-
regions, identifying the sampling strategies and criteria used by
countries to select positive specimens for virus isolation, and eval-
uating the impact of increasingly PCR-based surveillance on the
availability and representativeness of viruses reaching NICs.
Such analyses of regional submission patterns could potentially
aid in the revision and reﬁning of current WHO  guidance for NICs
on which viruses to share with WHOCCs and by when in order
to strengthen the VCM process and its outcomes [3]. At the same
time, NICs need to be able to recognize both usual and unusual
circulating viruses and to decide upon an optimum submission
strategy in the context of their own situation, particularly as the
timing of seasons varies. It also remains the case that virus sub-
mission patterns may  be adversely affected by external factors
in many countries, for example, customs requirements and other
causes of shipping delays. Although delaying the February VCM
deadline by up to three weeks could potentially bring signiﬁcant
gains, any such shift would have to be evaluated for feasibility
within the very narrow overall timeframes currently available for
vaccine development and manufacture. In the United States, the
WHOCC Atlanta has provided guidance to individual States on the
number of samples needed for different epidemiological situations.
Such an approach could help to improve the representativeness
of viruses, and may  also be applicable to other regions of the
world.
At the global level, following adoption of the PIP Framework and
other international initiatives, the demands placed on the GISRS
have expanded, with activities now including:
• comprehensive support for high-quality inﬂuenza surveillance
and virus detection, sharing and characterization;
• maintaining and enhancing electronic reporting platforms
such as WHO  FluNet (http://www.who.int/inﬂuenza/gisrs
laboratory/ﬂunet/en/) and FluID (http://www.who.int/inﬂuenza/
surveillance monitoring/ﬂuid/en/) to facilitate global reporting;
• the development and revision of WHO  guidance on epidemiolog-
ical and virological surveillance;
• supporting national capacity-building and sustainability
improvements (including through PIP Framework mechanisms
and the WHO  Shipping Fund);
• collaboration with vaccine manufacturers, associated laborato-
ries and regulatory agencies to facilitate vaccine-production and
licensing processes;
• supporting research into new surveillance and vaccine technolo-
gies;
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• strengthening collaboration with veterinary and other animal-
sector agencies working at the human–animal interface.
Ongoing efforts in these and other areas will be the key to meet-
ing the twin demands of continually improving inﬂuenza vaccines
while ensuring their availability to an increasingly larger propor-
tion of the world’s population.
2.2. Efforts to increase the availability of egg isolates
Inﬂuenza viruses isolated in eggs are still needed to meet cur-
rent regulatory requirements for vaccine manufacture. There are
three main challenges in obtaining such isolates, namely: low iso-
lation rates in eggs; the occurrence of egg-adaptive changes in the
haemagglutinin (HA) gene that can lead to changes in virus anti-
genic proﬁle; and other changes associated with the development
of high-growth reassortants (hgrs) for use in vaccine production.
Such difﬁculties continue to be compounded by the reduced provi-
sion of egg isolates by NICs.
Potential solutions to the problem of low isolation rates iden-
tiﬁed by the WHOCC Atlanta include increasing the age at which
embryonated eggs are inoculated from 9–10 days to 13–15 days;
changing the inoculation route to the allantoic cavity; and chang-
ing the egg incubation temperature from 33 ◦C to 35 ◦C. The use
of such approaches has progressively increased the percentage of
A(H3N2) viruses isolated from 0.8% in 2011 to 11% in 2013, with
the trend appearing to continue in 2014 (18% to date). Similar suc-
cess was also reported by the WHOCC London following a switch
to eggs obtained from a speciﬁc breed of hen. Modifying egg-
isolation parameters has thus resulted in signiﬁcantly improved
egg-isolation rates for A(H3N2) viruses in recent years. In relation
to the issue of egg-adaptive changes to the HA gene and further
changes associated with the development of hgrs, the use of egg/cell
paired viruses in routine virus characterization can reveal how dif-
ferences in the substrate used for virus propagation can impact
upon antigenic proﬁles, thus aiding selection of the best A(H3N2)
candidate vaccine viruses.
Further studies of the egg-adaptation pathways of A(H3N2)
viruses may  eventually allow for the selection of viruses that are
antigenically more similar to their mammalian cell propagated
counterparts. In the future, such issues may  be overcome alto-
gether through the use of alternative or emerging technologies
such as reverse genetics or the development of synthetic viruses. At
present, however, signiﬁcant adaptive mutations associated with
egg-propagated A(H3N2) viruses continue to occur and are being
monitored by WHOCCs (Fig. 2). Given the challenges inherent in
the isolation and characterization of A(H3N2) egg isolates, consid-
eration could be given in the short term to requesting that NICs
increase the submission of matching clinical materials along with
virus isolates to WHOCCs.
2.3. Efforts from vaccine manufacturers
The provision of human-vaccine serum panels by vaccine man-
ufacturers remains an essential element in the broad range of
well-established cooperative activities between the WHO  GISRS
and Industry [1,2]. Such panels enable assessments to be made
of the reactivity of pre- and post-vaccination sera with inﬂuenza
viruses of interest (both seasonal and pre-pandemic) and thus
generate extremely valuable data for the WHO  VCM. At the
request of WHO, manufacturers continue to provide human serum
panels from different regions of the world – either through
contracts or in the case of Europe as part of annual man-
ufacturer clinical trials. Following the decision to phase out
clinical trials from European Union annual update licensing
requirements (http://www.ema.europa.eu/docs/en GB/document
library/Scientiﬁc guideline/2014/07/WC500170300.pdf), alterna-
tive arrangements will be needed in this region and discussions
are now being held on the best way forward.
Through the International Federation of Pharmaceutical Man-
ufacturers & Associations (IFPMA) Inﬂuenza Vaccine Supply (IVS)
Task Force, Industry also supports research and development
into hgrs, which have long been used as the basis of inﬂuenza
type A components in seasonal inﬂuenza vaccines. As the difﬁ-
culties in obtaining A(H3N2) egg isolates in recent years have
at least partially been addressed, the number of such isolates
has greatly increased thus permitting the improved selection of
optimal high-yield strains for vaccine production. In addition to
Fig. 2. Egg adaptive changes in the HA of A(H3N2) inﬂuenza viruses.
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providing isolates of antigenic signiﬁcance to Industry and reassor-
tant laboratories, WHOCCs also perform the subsequent antigenic
analysis and sequencing of the resulting strains, thus highlight-
ing the interdependence of GISRS and Industry in producing hgr
vaccine viruses that are antigenically closely related to wild-type
viruses. Related advances such as the use of monoclonal rather than
polyclonal antibodies as selection reagents has the potential both to
signiﬁcantly accelerate the speed of production of reassortants and
increase the number of suitable candidate vaccine viruses. Recent
advances in inﬂuenza B reassortant technologies could also soon be
applied to overcome a currently rate-limiting step in inﬂuenza vac-
cine production, particularly as manufacturers move towards the
production of quadrivalent vaccines in which type B viruses will
require 50% of vaccine virus production capacity.
The IVS Task Force has also collaborated with several WHOCCs
and reassortant producers in evaluating the feasibility of devel-
oping virus isolates in qualiﬁed cell lines that would meet with
regulatory acceptance. Preliminary data indicate that MDCK qual-
iﬁed cell lines are suitable for inﬂuenza virus isolation, with
the majority of viruses produced retaining the properties of the
corresponding WHO  reference viruses. In conjunction with the
acceptable growth rates achieved using MDCK cell isolates in both
cell-culture and egg-based manufacturing processes, and the out-
come of risk assessments and supporting literature review, the
position taken by Industry is that the approach appears to be suit-
able. It is envisaged that a regulatory framework could be developed
for the use of cell isolates as candidate vaccine viruses, potentially
involving the provision of approved cell lines to WHOCCs if this
were feasible.
The use of “synthetic” technologies may  also bring signiﬁcant
gains by allowing for the accelerated production of better-matched
and high-yielding vaccine viruses. This technology was  used during
the 2013 H7N9 outbreak response, with the HA and neuraminidase
(NA) genes being synthesized and vaccine viruses rescued within
one week of the China CDC posting the genetic sequencing data.
Clinical trials indicated that the resulting vaccine was  both safe
and immunogenic. The routine early and continuous sharing of
sequencing data could lead to the full realization of the potential
public health beneﬁts to be gained using synthetic seeds, including
the acceleration of pandemic response activities, the rapid avail-
ability of higher-yielding and better-matched strains and the ability
to generate candidate vaccine viruses in multiple locations as soon
as epidemiological and virological data emerge. Other Industry
efforts in this area will include collaborative efforts to identify
genetic markers of yield that can be used to select for high-yielding
strains.
2.4. Collaborative animal inﬂuenza surveillance and response
activities
The importance of sustained and coordinated inter-sectoral
inﬂuenza surveillance at the animal–human interface, and of col-
laborative assessment of the risk of a human pandemic, continues
to be reﬂected in the FAO-OIE-WHO Tripartite Concept (http://
www.who.int/inﬂuenza/resources/documents/tripartite concept
note hanoi 042011 en.pdf?ua=1). Initiated in January 2011 and
renewed in January 2014 for a further 5 years, this concept sets
out the roles of both WHO  and the OIE-FAO Network of Expertise
on Animal Inﬂuenza (OFFLU) in coordinating global activities to
address health risks at the animal–human–ecosystems interface.
Recent progress has included improved sharing of viruses and
reagents for their characterization, and the increased availability
of appropriate OFFLU information and data at the biannual WHO
VCMs. Key information now routinely shared includes epidemio-
logical overviews and phylogenetic data of highly pathogenic avian
H5N1 in animals; the results of antigenic testing of speciﬁed isolates
using ferret-derived antisera; and information on a broad range of
animal viruses considered to be of public health concern, including
H9, H7 and H5 (other than H5N1) subtypes.
Long-standing obstacles to sustainable inﬂuenza surveillance
in animals include limited awareness of the need to manage
pandemic risks; the lack of drivers for non-notiﬁable inﬂuenza
surveillance; and associated absence of legislative frameworks. In
many settings, under-resourced veterinary services face challenges
in securing sustainable funding and obtaining industry involve-
ment, particularly when balancing ﬁnancial and other incentives
against potential disincentives. As a result, advocacy efforts are
still needed to further strengthen the commitment of national vet-
erinary agencies to global public health objectives, and to make
the case for the extra resources and increased awareness that are
needed to support the strengthening and sustaining of veterinary
services.
Improving inﬂuenza surveillance in farmed animal populations,
and clearly establishing the roles and responsibilities of all agen-
cies working in this area, will become increasingly necessary,
especially as surveillance capacities and technologies evolve. For
example, in 2004 the very limited capacity for H5 surveillance
led to the establishment of GISRS H5 Reference Laboratories and
the resulting close collaboration with OFFLU in a broad range of
surveillance, pandemic risk assessment and vaccine development
activities. Following a subsequent dramatic increase in H5 surveil-
lance, including by WHOCCs, consideration is being given to the
current role of H5 reference laboratories.
3. Improving the understanding of inﬂuenza activity and
addressing the complexities related to vaccines in tropical
regions
3.1. The concept of inﬂuenza transmission zones
WHO  is working to identify epidemiological “transmission
zones” in which countries with similar inﬂuenza activity and trans-
mission trends are grouped together in order to better reveal global
and regional patterns of inﬂuenza spread. Eighteen transmission
zones were provisionally created, initially based upon existing geo-
graphical regions and adjusted according to knowledge of inﬂuenza
transmission trends (Fig. 3). Following analysis of FluNet data sub-
mitted by countries that met  speciﬁed criteria, it was  concluded
that the provisionally identiﬁed zones did appear to consist of
countries exhibiting similarities in their patterns of inﬂuenza trans-
mission. Further time-series analyses were carried out to better
categorize tropical transmission patterns, again using countries
with continuous FluNet data for a speciﬁed period. In line with
recent published ﬁndings [4], statistical assessment of the num-
ber and timing of national inﬂuenza activity peaks indicated that
although inﬂuenza patterns deﬁnitely exist in tropical regions of
the world, such patterns were less evident than those observed in
the northern and southern hemispheres. Quality surveillance data
are now being generated to allow for more-detailed trend analyses
and for periodic review of transmission zone divisions.
Improving the methodology used and supplementing data with
literature reviews could lead to a greatly improved understanding
of global inﬂuenza trends; strengthened seasonal inﬂuenza pre-
paredness; and a more accurate assessment of burden of disease
to guide the development and expansion of national vaccination
policies. The continuous collection of both laboratory and epidemi-
ological inﬂuenza surveillance data will be the key to achieving such
goals. Current limitations include the reliance on national level data
which may  not be regionally representative, due for example to
the widely differing sizes of different countries. In some cases, data
may  not even be nationally representative due to wide variations in
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Fig. 3. Inﬂuenza transmission zones.
seasonal patterns across very large countries such as Brazil, China
and India. There is thus a need to better understand the underlying
factors that result in the creation of both broad transmission zones
and of regional outliers. As understanding increases, it may even
become feasible to reduce the number of transmission zones, while
still bringing about signiﬁcant practical reﬁnements and other ben-
eﬁts not available using the current three “de facto” zones (southern
hemisphere, northern hemisphere and the tropics).
3.2. Addressing the complexities related to inﬂuenza vaccines in
tropical regions
WHO  issues its recommendations for inﬂuenza vaccine formu-
lations in February and September each year in preparation for the
corresponding northern and southern hemisphere inﬂuenza sea-
sons (November–April and May–October respectively). However,
in tropical regions of the world, such well-deﬁned seasonality does
not always occur. For example, in Kenya and many other countries
in tropical Africa, inﬂuenza viruses circulate year-round and despite
limited epidemiological data, there is growing evidence of a signiﬁ-
cant burden of inﬂuenza disease in the region. Following improved
surveillance and virus-sharing efforts in Kenya and other African
countries, it appears that selected priority populations would stand
to beneﬁt from receiving either the northern or southern hemi-
sphere vaccine formulation. Further work is needed to evaluate
the optimal delivery mechanisms in a country with almost year-
round virus circulation, and to determine the added beneﬁts and
costs of strategically using both vaccine formulations as opposed
to a single formulation. As inﬂuenza vaccine use in tropical Africa
grows, more data will be needed in countries to inform national
vaccination policies.
In the American tropics, similar issues exist in determining the
degree of inﬂuenza seasonality, predicting annual transmission
patterns and selecting between southern or northern vaccine for-
mulations. An analysis of data from countries in the region found
that for many countries inﬂuenza epidemics typically occurred
between May  and September during the austral winter and lasted
for 4–5 months, rather than year round. Although the speciﬁc for-
mulation used in individual countries varies, an estimated 81%
of the predominant strains in the American tropics were repre-
sented in the southern rather than northern hemisphere vaccine
formulation, with the result that this was  the most up-to-date com-
position. The viruses that circulate in the American tropics tend
to be similar throughout the region but those characterized as
predominant one year in a particular sub-region tend to become
dominant in other sub-regions in successive years in a clearly dis-
cernible geographical order.
In Americas, inﬂuenza activity in the tropics is often preceded by
the release of the southern hemisphere vaccine and by Vaccination
Week in April each year. Against this regional backdrop, national
patterns of inﬂuenza transmission and seasonality are complex.
Nevertheless, as quality surveillance data become available for
more years, the optimal timing of vaccination is likely to become
clearer. In Brazil, a large latitudinal range encompassing both
temperate and tropical regions, with good epidemiological data
available in certain of its sub-regions, provides an example of how
the optimum timing of vaccination cannot be reduced to the current
northern–southern hemisphere paradigm. One study comparing
the historic use of southern hemisphere vaccine recommendations
and schedule against a hypothetical northern hemisphere vaccine
scenario concluded that a higher degree of matching between cir-
culating and vaccine viruses would have been achieved had the
northern hemisphere vaccine composition and vaccination sched-
ules been followed [5]. Although based on relatively few virus
isolates, this study highlights the complexities of inﬂuenza vacci-
nation in a large tropical country.
Although most tropical countries in the Asian region technically
lie in the northern hemisphere, they do not exhibit the inﬂuenza
seasonality seen in temperate regions, with some level of inﬂuenza
virus circulation typically occurring throughout the year. Asian
countries lying between the equator and approximately 30◦ N in
latitude experience a peak in inﬂuenza during the monsoon sea-
son (June–September). In countries closest to the equator, there is
year-round circulation with no discrete peak season. In order to
better understand patterns of inﬂuenza virus transmission in the
region and inform national vaccination approaches, a study was
conducted which aimed to characterize inﬂuenza seasonality in
tropical and subtropical countries of southern and south-eastern
Asia; identify latitude gradients associated with discrete seasona-
lity; and determine the best time of the year for national inﬂuenza
vaccination campaigns [6]. Weekly surveillance data from 10
Asian countries over the period 2006–2011 clearly indicated peak
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periods of inﬂuenza activity in seven of the countries, with no
distinct seasonality in the remaining three. In many cases, it
was apparent that the current vaccination schedules used were
suboptimal and that most tropical countries in Asia might beneﬁ-
cially consider conducting vaccination in April–June each year, i.e.,
prior to inﬂuenza peak circulation, using the most recent WHO-
recommended vaccine formulation.
Compiling and sharing data on inﬂuenza from individual
countries in a given region appears to potentially allow for a
regional consensus to be reached on the circulation patterns and
seasonality of inﬂuenza, which could also incorporate latitudinal
differences. At present, the effects of climatic factors in particular
are poorly understood especially in remote areas of large tropical
countries and in countries where the required data remain sparse.
Even in those tropical countries where there are likely to be at least
two peaks of inﬂuenza activity each year, improved knowledge of
the main peak has the potential to result in improved vaccination
approaches. Across all the tropical regions of the world there now
appears to be a paradigm shift occurring based upon improved
understanding of the extent to which inﬂuenza is seasonal in order
to strengthen national vaccination policies and select vaccines of
optimal composition.
4. Improving the characterization and selection of
inﬂuenza vaccine viruses
Maintaining good levels of inﬂuenza vaccine effectiveness [7]
requires regular vaccine composition updating and annual admin-
istration. Until radically different approaches such as the use of
universal inﬂuenza vaccines become feasible, the updating process
is likely to remain based primarily upon the antigenic characteri-
zation and selection of egg-isolated (and potentially cell-isolated)
candidate vaccine viruses for the production of both inactivated
and live attenuated vaccines. WHOCCs combine the data obtained
from the antigenic characterization of viruses using HAI and virus
neutralization assays and the serological reactivity of pre- and
post-vaccination human sera with extensive genetic sequencing
data and epidemiological and clinical information. The resulting
datasets form the scientiﬁc basis for expert consideration at the
biannual WHO  VCMs.
Despite being the traditional assay of choice since the 1940s,
there remain a number of limitations and difﬁculties associated
with the use of HAI assays. As a result, a range of corrective tech-
niques and complementary assays are used by WHOCCs and other
GISRS laboratories [2]. Efforts are also currently under way  to
address issues such as the differential reactivities of egg-derived
and cell-derived viruses with ferret sera, and the complications
arising from the binding of the virus NA surface protein to red blood
cells. As a result, new approaches continue to be needed to improve
assay sensitivity and accuracy, streamline the throughput of sam-
ples and improve the reproducibility of data between laboratories.
Such approaches would also need to be sufﬁciently ﬂexible to be
used in the analysis of antibody responses to emerging viruses.
Until signiﬁcant advances are made in the development of new
laboratory assay platforms and/or vaccine technologies WHOCCs
will continue to face acute time pressures, particularly around the
time of the biannual VCMs. Any requirement for the introduction
of further assays, or for the greatly expanded use of existing but
selectively applied approaches such as microneutralization (MN)
assays, are likely to prove problematic, particularly given the rate-
limiting step of growing viruses and developing the reassortants
required for some assays. Realistic aims at present would appear to
include the more-optimal use of HAI and other assays; improved
understanding of the data produced by neutralization assays; and
strengthening of national and global initiatives such as CONSISE
(Box 1) for the standardization of serological testing methods.
Box 1: CONSISE—a global standardization and
information-sharing platform of influenza seroepi-
demiology
Early in the course of the 2009 H1N1 pandemic it was realized
that there was a need for timely and standardized seroepide-
miological data to better estimate disease severity and attack
rates during non-seasonal events in order to inform policy
decisions. Following its establishment in 2011, the Consor-
tium for the Standardization of Inﬂuenza Seroepidemiology
(CONSISE) has worked to standardize the seroepidemiology
of inﬂuenza and other respiratory pathogens, and to develop
comprehensive investigation protocols for use in responding
to both seasonal and potentially pandemic inﬂuenza viruses,
and other respiratory pathogens. CONSISE now has more than
100 members in over 40 countries who openly and freely share
study and laboratory assay protocols and other information on
the internet (https://consise.tghn.org/).
A number of CONSISE evaluation and standardization studies
were conducted to assess and improve the standardization of
antibody assays worldwide. Despite the publication of WHO
protocols for both HAI and MN assays [9] signiﬁcant variations
were found between laboratories in terms of assay protocols,
and in the determination and expression of endpoint titres.
New consensus protocols for the HAI assay, 2-day enzyme-
linked immunosorbent assay (ELISA) MN assay and 3-day HA
MN assay were therefore developed and published based upon
“required” or “recommended” parameters.
During the 2013 H7N9 event, CONSISE in its capacity as a
unique international forum for seroepidemiology laboratories
organized a teleconference and promptly published web-based
protocols for the detection of antibodies to the emerging virus.
Attempts to overcome the inherent limitations of the traditional
HAI assay through the development of assays based upon synthetic
beads or solid matrices have had only limited success. Studies into
the development of synthetic red blood cells consisting of beads
coated in either puriﬁed natural glycans or synthetic sialyl-glycans
have highlighted that, despite evidence of high reproducibility, a
range of complex issues (including the prohibitive cost of synthet-
ically produced glycans) would need to be addressed before the
approach could become feasible. Efforts to harness a number of
non-bead technologies based upon the use of sialyl-glycans or red
blood cell membrane fragments is ongoing. Despite the adoption
of multiple strategies for developing HAI replacement assays, no
viable alternative has yet emerged. The development of such assays
would be enhanced by improved understanding of the glycans rec-
ognized by different inﬂuenza types/subtypes.
As previously reported [2], the NA surface protein plays a key
role in the life cycle of the inﬂuenza virus and its transmission.
Despite ongoing high levels of interest in the potential role that
antibodies to NA could play in the development of more-effective
vaccines, there is presently no regulatory requirement for the pre-
cise determination and standardization of vaccine NA content.
Nevertheless, different NA subtypes are known to be genetically
distinct, exhibit discontinuous antigenic drift and give rise to anti-
bodies associated with protection against homologous, and to a
lesser extent heterologous, inﬂuenza viruses. Efforts are therefore
continuing to improve understanding of the patterns of antigenic
drift in the NA of seasonal inﬂuenza viruses.
The application of “antigenic landscape” modelling approaches
may  also provide enhanced understanding of the quality and
breadth of human antibody responses elicited against HA (and
potentially against NA) following infection or vaccination, and of
the inﬂuence of prior immunity on vaccination responses. If corre-
sponding advances in predicting the course of viral evolution prove
to be feasible then such approaches could be used to inform and
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evaluate vaccination strategies. Antigenic mapping (cartography)
techniques have been studied for about ten years and despite vari-
able red blood cell binding effects, and other practical issues, can
help to visualize the antigenic evolution of predominant viruses
[8]. Antigenic landscaping approaches have now been used to
examine historic HAI datasets from a household cohort study in
Viet Nam in order to recreate the recent course of inﬂuenza virus
evolution and explore pre- and post-infection responses. Obser-
vations of increasing immunity over time clearly highlighted a
persistent “back-boost” effect in which vaccination with antigeni-
cally advanced vaccines appeared to stimulate a recall of previous
antibody responses. In terms of vaccination strategies such a phe-
nomenon may  imply that the optimum vaccine strain to use might
be ahead of the centre of the current cluster of evolving strains, thus
providing both recall beneﬁts as well optimal de novo responses
to new epitopes. By combining such insights with improved pre-
dictions of the course of future virus evolution it may  be possible
to improve the vaccine virus selection process and increase the
effectiveness of inﬂuenza vaccines. At present, there are a number
of practical and theoretical assumptions underlying the approach
and further studies are required. These could include prospective
studies of vaccination with an antigenically advanced virus; stud-
ies across different age groups; and studies based upon data from a
range of alternative laboratory assays (such as NA assays, MN and
assays that detect stalk-reactive antibodies).
5. New technologies and tools for improving inﬂuenza
vaccine virus selection
A number of emerging new technologies and tools have the
potential to revolutionize inﬂuenza virological surveillance and
response activities. In the context of national surveillance activities,
the increasingly routine use of whole genome sequencing and other
high-throughput approaches in large and technologically capable
NICs is providing signiﬁcant insights in areas such as virulence
assessment, phylogenetic and transmission studies and evaluation
of antiviral susceptibility. As such high-throughput methodologies
change the focus of surveillance away from single HA and NA char-
acterization and towards whole genome sequence determinations
they will become not only a key element in outbreak investigations
but will also drive a shift towards a new surveillance paradigm
(Fig. 4).
Further development and increased availability of next-
generation sequencing and associated technologies and equip-
ment, together with reduced operating costs and data-analysis
requirements, could also allow for the examination of global gene
expression at the level of pathogen and host. Such approaches
have the potential not only to greatly improve understanding of
circulating viruses and their evolution, but to reveal the nature
and extent of intrahost viral diversity and degree of ﬁtness; sig-
nal the potential emergence of drug resistance; aid in vaccine virus
selection and allow for the accurate assessment of risk, including
pandemic risk. Datasets and pipelines could also be rapidly gener-
ated for examining genetic variation in populations of viruses that
may  be associated with a particular phenotype. The use of synthetic
genomics technologies based on the sequencing data obtained
would then allow for the rapid synthesis for future use of “libraries”
of numerous HA, NA and other gene segments. Efforts under way
in this area include the National Institute of Allergy and Infectious
Diseases (NIAID), National Institutes of Health (NIH)-supported
Synﬂuenza project at the J. Craig Venter Institute (http://gsc.
jcvi.org/projects/gsc/Synﬂuenza/index.php) and the United States
Department of Health and Human Services (HHS)-supported syn-
thesis of whole viruses for vaccine production (as occurred during
the production of inactivated H7N9 vaccines in 2013) and for asso-
ciated challenge, transmission and pathogenesis studies.
As evidenced in 2013, assessing and responding to the risk to
human health posed by zoonotic inﬂuenza infections is currently
highly problematic for national surveillance systems. Substantial
viral diversity exists within animal populations, even within the
same subtype, and only limited genetic sequencing and antigenic
data are typically available. Responding to outbreaks of zoonotic
inﬂuenza viruses is also compounded by pronounced variability
in their growth properties. Efforts undertaken to address this sit-
uation include virus-challenge studies conducted at the WHOCC
Memphis, which have highlighted a number of potentially attain-
able beneﬁts of genomic and bioinformatics approaches to avian
inﬂuenza surveillance, while providing insights into the method-
ological and other challenges that will need to be overcome. In
addition, a case study conducted by the United States CDC, and
based upon clinical samples taken during the H7N9 event in
China, indicated that despite multiple challenges, properly applied
next-generation sequencing technologies to detect and assess the
properties of emerging intrahost genetic variants can lead to
improved risk assessment. Studies have also been conducted on
the potential of use of reconstructed ancestral A(H5N1) inﬂuenza
viruses to develop cross-clade protective vaccines [10], and on the
utility of reverse genetics techniques to improve H5N1 vaccine
virus growth rates [11]. Long-term goals in efforts to detect and
respond to zoonotic inﬂuenza outbreaks include the routine use of
surveillance and risk-assignment activities based upon the use of
genetic sequencing data, followed by the use of reverse genetics
approaches to rapidly generate suitable candidate vaccine viruses.
Despite the advances made to date, signiﬁcant challenges will
need to be addressed before next-generation technologies become
a routine part of national surveillance and response paradigms, par-
ticularly in low-resource settings. These include the need to fully
understand the utility of more-comprehensive genomic datasets
in vaccine virus selection and development. In addition, the use
of current technology platforms requires considerable expertise,
with advanced research and development efforts now under way
to reﬁne and harmonize the pipelines and bioinformatics tools
required at different stages of the process. Bioinformatics demands
in particular remain high given the ever-evolving nature of instru-
mentation and protocols, and the costs associated with the analysis
of sequencing data.
Interest also remains high in the development and potential
applicability of mathematical modelling approaches for predict-
ing the course of inﬂuenza virus evolution, and thus potentially
accelerating the selection of new vaccine viruses. Recent work on
integrating data on the antigenic and genetic evolution of inﬂuenza
viruses indicates that such a combined approach can provide
potentially valuable new insights into the factors that determine
observed patterns of antigenic drift [8]. By pinpointing the precise
mechanisms by which changes in viral genes result in antigenic
change it may  soon be feasible to predict which of the viruses circu-
lating at the start of the inﬂuenza season will come to predominate
in terms of number of new infections. The related concept of viral
“ﬁtness” provides a further potential means of evaluating and pre-
dicting patterns of virus evolution. This approach is based upon
the integration of publicly available HAI, sequence and biophysical
data plus regional information to develop a joint epitope/non-
epitope ﬁtness model. Preliminary retrospective studies indicate
that such an approach can successfully predict the evolution of HA
sequence clades year on year. The predictive potential of such a
model at the phenotypic level remains to be demonstrated. Poten-
tial further improvements and reﬁnements include more-rigorous
data-quality control, use of a wider range of input-data categories
and improved integration of selected datasets.
Approaches based on systems genetics and systems biology con-
cepts also have the potential to provide valuable new insights.
Systems genetics approaches can capture human genetic diversity,
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Fig. 4. Paradigm shift—the new surveillance pyramid.
and allow, for example, the identiﬁcation of the speciﬁc host-
susceptibility genes that regulate disease outcomes following viral
infections. Systems biology approaches provide an opportunity to
generate new types of datasets with the potential to identify both
diagnostic and prognostic markers; understand pathogenic and vir-
ulence mechanisms; evaluate vaccine performance and responses;
generate improved cell lines for virus cultivation; and identify
correlates of protection. Despite being at an early stage, systems
biology approaches allied to current statistical capabilities could
feasibly be used to elucidate some of the molecular correlates of
immune responsiveness and related immunogenicity issues. Such
associative studies may  soon be feasible in the context of clinical
trials to determine their potential application. However, in terms
of understanding causality much remains hypothetical at this stage
and further work is required to identify the key pathways of interest
and develop effective therapeutic approaches. As viruses rely upon
host factors to replicate, and often hijack the cellular processes initi-
ated in response to infection, such approaches could even be based
upon the suppression of host responses.
Human inﬂuenza vaccine responses and course of infection have
also been evaluated during a longitudinal study which combined
genetic, transcriptional and immunological data [12]. Such an inte-
grative genomics approach allows for the identiﬁcation of host
genetic factors that contribute to variations in vaccine responsive-
ness, and may  uncover important mechanisms affecting vaccine
efﬁcacy. The results indicate that genetic variations between indi-
viduals are important determinants of vaccine immunogenicity.
Understanding the complex mechanisms that underlie variations
in vaccine responses may  allow for the identiﬁcation of individ-
uals who do not develop a protective antibody response following
inﬂuenza vaccination. Appropriate modiﬁcations to the dose or
vaccine type given to such individuals could potentially lead to a
reduction in the proportion of the population who would otherwise
remain unprotected. The approach may  also be useful in guiding the
modiﬁcation of factors, such as adjuvant use, intended to enhance
the immune response to inﬂuenza vaccines in all recipients.
Taken together, the range of new technologies and tools now
under development are capable of generating potentially huge vol-
umes of highly complex and diverse datasets. Recent trends in
the acceleration of data volumes, velocity and variety are driv-
ing a newly emerging concept of “big data” (Fig. 5). Efforts will
be required to ensure the availability, accessibility and qual-
ity of the data generated, including through the validation of
datasets; to enable the meaningful integration of often highly
Fig. 5. The three “V”s of big data.2
disparate datasets; and to ensure the broadest possible relevance
and application of the resulting ﬁndings. As part of its activities
in these areas, the NIAID/DMID Genomics Program has invested
in a number of Bioinformatics Research Centers (BRCs), including
the Inﬂuenza Research Database (www.ﬂudb.org). This free-to-use
comprehensive collection of inﬂuenza-related data and analysis
tools is intended to support a process of data standardization and
integration encompassing a range of sequence, surveillance and
immunological data categories.
In addition to expanded data volumes and the accelerated
velocity of data generation, current efforts to map  the organizing
principles of big data and its application increasingly highlight the
need for parallel advances in the underlying knowledge base and
interpretive context in which to set the data generated. Discerning
the key patterns in data relies crucially on the capture of data vari-
ety (“metadata”). A collaborative United States Genome Sequence
Centers-BRC metadata working group has now been established in
an attempt to support the capture of relevant, standardized and
2 Source: Journal of PayDeg. Issue 03. August 2012 (http://paydeg.com/
CloudComputing3.html, accessed 20 April 2015).
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consistently reproducible metadata by its member projects. Har-
nessing the currently theoretical beneﬁts of concepts such as big
data for the inﬂuenza vaccine virus selection and development
process will depend upon consolidating and building upon these
and further advances in the generation, integration, analysis and
dissemination of potentially huge and complex datasets.
6. Manufacturing and regulatory aspects of improved
vaccine virus selection and development
Over the last decade, growing awareness of inﬂuenza as an
important global public health issue has been coupled to increas-
ing demands for more-equitable access to effective and affordable
inﬂuenza vaccines. However, efforts to increase global vaccine pro-
duction by establishing manufacturing and regulatory capacity in
some developing countries have met  with a number of challenges.
In Brazil, for example, inﬂuenza vaccine production at the Butantan
Institute was initiated through a technology-transfer programme
involving Sanoﬁ Pasteur that started in 1999 and was  completed
in 2010 as part of the WHO  Global Action Plan for Inﬂuenza Vac-
cines (GAP). The transferred technology enabled the manufacture
of egg-based split virus vaccine with an annual production capac-
ity of 20 million doses, based primarily upon the estimated size
of the elderly population targeted in national policy for vaccina-
tion in 1999. This unprecedented initiative proved to be a long
and involved process for all stakeholders, including government,
Sanoﬁ Pasteur and the federal Brazilian regulatory agency Agência
Nacional de Vigilância Sanitária (ANVISA). However, despite the
obstacles encountered, the technology-transfer process not only
resulted in seasonal vaccine production in Brazil, but also allowed
for the development and production of H5N1 vaccines, pandemic
H1N1 vaccine lots for clinical studies and H7N9 vaccine lots for
pre-clinical studies. Current challenges include the need to acceler-
ate vaccine production and to conduct clinical trials as required by
ANVISA, and overcoming the distribution logistics associated with
a vast land area. It is intended that improvements in the acquisition
of eggs, reassortants and reagents; strengthened communications
with federal customs and ANVISA; improved collaboration with
inﬂuenza reference laboratories; and enhanced production plan-
ning will result in an increased production capacity sufﬁcient to
meet the needs of a range of newly identiﬁed groups targeted for
inclusion in expanded national inﬂuenza vaccination policies.
Successfully completing each step in the annual inﬂuenza
vaccine manufacturing cycle relies upon timely and regular
communication between the WHO  GISRS, manufacturers and reg-
ulatory authorities. For northern hemisphere vaccines, production
must begin almost a year in advance of their eventual deployment
(Fig. 6). The seasonally shifted schedule for southern hemisphere
vaccines involves a shorter lead time between the WHO  VCM
announcement in September and ﬁnal formulation and distribu-
tion. Despite early access by manufacturers to epidemiological data,
regular teleconferences prior to the VCM and prompt information
on available reassortants and reagents, at least one component
virus of seasonal inﬂuenza vaccines must be manufactured “at
risk” and up to two working seeds prepared prior to the WHO
VCM (Fig. 6). Subsequent steps in the manufacturing cycle are
equally time critical and include the optimization and validation
of the manufacturing process; the supply of calibrated reagents for
the single radial immunodiffusion (SRID) assay by ERLs; and the
need to annually update the product licences in an often complex
regulatory and manufacturing environment. These timelines have
now come under further pressure with the introduction of sev-
eral quadrivalent vaccines. In view of such time constraints, there
appears to be no obvious means of accommodating any proposal
to improve the representativeness of viruses sent to WHOCCs by
strategically delaying the timing of the WHO  VCM.
Eliminating avoidable delays in the vaccine production cycle
caused by the use of suboptimal PR8 master donor viruses remains
a key aim, including during the time-critical development of can-
didate pandemic vaccine viruses. The United States Biomedical
Advanced Research and Development Authority (BARDA) is work-
ing to develop panels of optimized viral “backbones” that can
be selectively used in the accelerated production of inactivated
inﬂuenza vaccines. Three representative PR8 donor viruses from
GISRS partner laboratories were compared in terms of their impact
on HA yield across a broad range of different inﬂuenza virus sub-
types and lineages. In some subtypes (for example, the H5N1 strain
A/Hubei/1/2010) optimizing the PR8 internal genes was associated
with an up to eight-fold increase in HA yield compared to subopti-
mal  donor use. Although the switch to a 5:3 genotype (containing
wild type PB1 as well as HA and NA genes) generally had detrimen-
tal effects on the yields achieved with the classical 6:2 genotypes,
this did not apply to certain low-yielding 6:2 viruses in which yield
could be doubled.
In terms of vaccine potency, SRID tests remain the established
gold standard for determining the antigen content of inﬂuenza
vaccines, with studies indicating acceptably low inter-laboratory
variability. However, the 2009 H1N1 pandemic placed increased
pressures on vaccine production and release timelines, with clin-
ical trials being either required or desirable. The availability and
early use of other types of vaccine potency assays prior to the
production of SRID reagents early in the pandemic resulted in
renewed interest in the development of alternative approaches.
The leading candidates are either physicochemical assays –
such as high-performance liquid chromatography (HPLC); sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE);
and mass spectrometry – or biological assays (“bioassays”) such
as ELISA/enzyme immunoassay (EIA); surface plasma resonance
(SPR); and immunocapture isotope dilution mass spectrometry (IC-
IDMS). Physicochemical assays potentially have the advantages of
being immediately available, rapid, reproducible and well suited
for use in automated high-throughput approaches. Disadvantages
include the inability to take into account the conformation, anti-
genicity or immunogenicity of the measured HA; the potential need
for reference reagents; and the expense and technical difﬁculty of
some methods. Bioassays measure vaccine biological activity or
reactivity and are usually speciﬁc for the antigen being assayed.
Their main advantage is their potential for measuring biologi-
cally active HA and for evaluating its stability. Moreover, some
assay formats, such as ELISA, are already well established and
easily implementable. Disadvantages include the need for speciﬁc
reagents and the expense and technical complexity of some assays.
Despite this, bioassays are preferred over physicochemical assays
with the combination IC-IDMS assay also offering some potential.
Workshops have now been held and studies initiated to compare
and evaluate a range of physicochemical and biological assays as
potential alternatives to SRID.
In the United States, regulatory experience at the Food and Drug
Administration (FDA) Center for Biologics Evaluation and Research
suggests that the current inﬂuenza vaccine virus selection process
generally works well, and does not in itself present signiﬁcant reg-
ulatory issues for vaccine manufacturing. However, the required
analysis of manufacturer’s seed viruses and the preparation and
calibration of potency reagents are highly resource intensive. This
situation is now being exacerbated by an increase in the num-
ber of available reference viruses and the licensure of new vaccine
manufacturers. In addition, recent licensure processes for quadri-
valent, cell-based, recombinant-protein and adjuvanted vaccines
have highlighted a number of regulatory challenges associated with
new inﬂuenza vaccine types.
For quadrivalent vaccines, licensure is based upon safety and
immunogenicity studies and the demonstration of non-inferiority
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Fig. 6. The manufacturing cycle for inﬂuenza vaccines for use in the northern hemisphere winter season.3
to licenced trivalent vaccines. Related key issues include the need
for four sets of speciﬁc reagents for potency testing; the potential
for both wild-type and reassortant viruses to be used as vac-
cine viruses; and cross-reactivity and other difﬁculties in SRID
and identity testing arising from the relatedness of the two B lin-
eages. Inﬂuenza B strains are also typically the slowest growing
strains and the lack of ideal high-growth reassortants may  result
in manufacturing and lot-release delays. Currently, there is only
one mammalian cell based inﬂuenza vaccine licenced in the United
States, with studies indicating that initial concerns around the
potential tumorigenicity of MDCK cell lines were unfounded. A sin-
gle recombinant protein inﬂuenza vaccine has also been licenced
in the United States and is based upon an insect virus (baculovirus)
expression system and recombinant DNA technology. Although
candidate vaccine viruses are not needed to produce such a vaccine
(only sequence information for the recommended HA is needed)
there are likely to be issues in relation to the determination of
appropriate potency assays and current lack of established path-
ways for product improvement.
Any development and licensure pathway for adjuvanted vac-
cines will require careful attention to preclinical testing, study
design, dosing decisions and safety monitoring. The complex nature
of adjuvants and adjuvanted vaccines necessitate the collation
of extensive safety data, including clear indications of duration
of follow-up, monitoring of adverse events of special interest
and a focus on the potential for autoimmune/auto-inﬂammatory
disease development. The only adjuvanted inﬂuenza vaccine cur-
rently licenced in the United States is an AS03-adjuvanted H5N1
3 Source: International Federation of Pharmaceutical Manufacturers & Associa-
tions (IFPMA) Inﬂuenza Vaccine Supply (IVS) Task Force.
monovalent vaccine produced under government contract as
part of national pandemic preparedness. A detected association
between narcolepsy and AS03 following the use of 2009 H1N1
pandemic vaccines in a small number of Scandinavian countries
highlights the case-by-case approach required while emphasizing
the need for appropriate safety data for all adjuvants.
The emergence of potentially pandemic inﬂuenza viruses cre-
ates speciﬁc regulatory and associated challenges in terms of
clinical study design, timeline and interim data analysis. Over-
coming such challenges requires collaboration and cooperation
between multiple agencies and manufacturers. Since 2009, NIAID
clinical vaccine trials have been conducted to determine the appro-
priate response to emerging inﬂuenza viruses in both pandemic
and non-pandemic scenarios. The ongoing emergence of multi-
ple potentially pandemic inﬂuenza viruses (such as A(H3N2)v,
A(H5N1) and A(H7N9) viruses) will continue to create challenges
for vaccine development in terms of clinical trial study design and
resource requirements. During the 2009 H1N1 pandemic, 12 clini-
cal trials were undertaken by the NIAID in the context of the United
States national emergency preparedness framework. These studies
were complementary to planned Industry trials, and were primar-
ily intended to generate data on safety and vaccine use in selected
populations.
Despite the challenges and constraints of current vaccine-
production technologies, the inﬂuenza vaccine landscape contin-
ues to be dominated by egg-based inactivated and live attenuated
vaccines, with a small number of cell-based and recombinant vac-
cines. During a pandemic all these platforms would potentially
necessitate antigen-sparing strategies and possibly gains in manu-
facturing efﬁciencies to meet demand. While the ﬁeld of inﬂuenza
vaccines thus appears to be moving towards a variety of niche
products in the near term, it is apparent that the ultimate goal
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remains the development of “universal” inﬂuenza vaccines offer-
ing longer-lasting immunity against a broad range of inﬂuenza A
virus subtypes. Such vaccines would likely remove the need for
annual vaccine virus selection, reduce production costs, eliminate
potential vaccine mismatches and shortages, and greatly increase
the global supply of both pandemic and seasonal vaccines.
7. Conclusions and future directions
Virological and epidemiological surveillance is the foundation
of the inﬂuenza vaccine virus selection and development pro-
cess, and national, regional and global efforts will continue to be
needed to improve monitoring and reporting activities, and to
ensure the timeliness and representativeness of virus sharing. In
many countries, much remains to be done in establishing, expand-
ing and sustaining ILI and SARI sentinel surveillance, motivating
staff, improving laboratory capacity and providing training for
sub-national and regional laboratory personnel. In some parts of
the world, severe economic and/or logistical hurdles continue to
restrict the timeliness and temporal and geographical represen-
tativeness of the viruses sent to WHOCCs for detailed analyses.
To help countries make the best use of available resources while
meeting their obligations under the PIP Framework, WHO  and
its partners will continue to work to develop regional and global
guidance on optimal approaches for ensuring the timeliness and
representativeness of inﬂuenza isolates and clinical specimens
shared with the WHO  GISRS.
Improved knowledge of inﬂuenza transmission “zones” could
allow for reﬁned and more-targeted surveillance activities, and
greater understanding of virus circulation and transmission pat-
terns, including in tropical regions. Further reﬁnement of the
currently provisional basis used to determine functional inﬂuenza
transmission zones should be considered. Even without the devel-
opment of speciﬁc recommendations for tropical areas, such an
approach could bring about much-needed improvements in cur-
rent guidance on where and when to use northern or southern
hemisphere inﬂuenza vaccine formulations in tropical countries.
As part of this, consideration could also be given to promoting the
wider use and potential reﬁnement of reporting platforms such
as WHO  FluNet and FluID, for example to accommodate multi-
ple seasonality and/or wide geographical variety within a single
country.
The need for sustained and coordinated inter-sectoral inﬂuenza
surveillance at the animal–human interface, and collaborative
assessment of the risk of a human pandemic, continues to be
reﬂected in the FAO-OIE-WHO Tripartite Concept (“One Health”).
Given the long-standing obstacles in implementing sustainable
inﬂuenza surveillance in animals, and in building upon recent
progress in integrating the outcome of this into the public health
context, improved collaboration between the WHO  GISRS and
OFFLU is needed.
Opportunities to improve the antigenic characterization and
selection of inﬂuenza vaccine viruses include the strategic use of
neutralization assays to support HAI assay data, and the further
strengthening of standardization and information-sharing initia-
tives. Efforts to develop alternative simpliﬁed and high-throughput
methods and quantitative assays will also continue, along with fur-
ther research into the utility of approaches based upon the use of
synthetic red blood cells, characterization of virus NA and antigenic
landscape technologies. Realistically, such aims must be weighed
against the ﬁnite capacity of WHOCCs to antigenically characterize
candidate viruses in typically limited timeframes.
A number of emerging new technologies and tools have the
potential to revolutionize inﬂuenza virological surveillance and
response activities. These include the increasingly routine use of
whole genome sequencing and other high-throughput approaches,
and the potential application of synthetic genomics, systems genet-
ics, systems biology, mathematical modelling and bioinformatics
approaches. However, despite the advances made to date, signiﬁ-
cant challenges will need to be addressed before such technologies
become a routine part of national surveillance and response
paradigms, particularly in low-resource settings.
Although vaccine technology is evolving, and despite long-
recognized challenges and constraints associated with current
vaccine-production technologies, the inﬂuenza vaccine landscape
continues to be dominated by egg-based inactivated and live atten-
uated vaccines, with a small number of cell-based and recombinant
vaccines. The research and development of hgrs will for the foresee-
able future continue to be a major focus of Industry and government
agency efforts as such viruses form the basis of the inﬂuenza type
A components of current seasonal inﬂuenza vaccines.
While the pipeline of inﬂuenza vaccines appears to be moving
towards a variety of niche products in the near term, it is apparent
that the ultimate aim remains the development of effective “univer-
sal” inﬂuenza vaccines that offer longer-lasting immunity against
a broad range of inﬂuenza A subtypes. In this and other related
areas of research and knowledge development, WHO  and its part-
ners will work to ensure that the advances made are translated into
improved inﬂuenza preparedness and response activities and into
far more equitable global public health outcomes.
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